-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Diabetes is a metabolic disease, and the number of diabetic patients in China is huge
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
That is, 1 in 10 people may be diabetic
.
On the whole, domestic diabetic patients still have a large unmet demand, which also means that the market space for hypoglycemic drugs is broad
.
Therefore, in the face of the huge market for diabetes drugs, many pharmaceutical companies are competing for layout, and the market competition is becoming more and more intense
.
But at the same time, with the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years
.
A few days ago, the website of the State Food and Drug Administration showed that Chongqing Yaoyou Pharmaceutical's Acarbose Tablets and China Resources Secco Pharmaceuticals' Acarbose Tablets were approved for production on the same day as Class 4 imitations, which are regarded as over-reviews
.
It is reported that on the evening of March 21, China Resources Shuanghe announced that recently, China Resources Secco Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "China Resources Secco"), a wholly-owned subsidiary of the company, has received Acarbo Sugar Tablet "Drug Registration Certificate" (Certificate No.
: 2022S00199), which approved the production of this drug
.
According to public information, the original research of acarbose tablets was developed by Bayer.
It was first listed in Germany in 1990.
It is one of the main products in the field of diabetes drugs.
It belongs to the basic treatment of hyperglycemia and has a good effect on reducing postprandial blood sugar.
It is a heavyweight oral hypoglycemic drug
.
It can reduce the risk of cardiovascular disease.
At the same time, the product is effective for a long time and safe to use.
It is mainly used for type 2 diabetes and postprandial blood sugar treatment for people with impaired glucose tolerance
.
According to data, in 2020, the total sales of acarbose tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 4 billion yuan
.
At present, 15 domestic companies have the production approval documents for acarbose tablets, among which 13 companies including Shandong Lukang Pharmaceuticals, CSPC Ouyi Pharmaceuticals, Hunan Qianjin Xiangjiang Pharmaceuticals, and Lepu Pharmaceuticals have reviewed them
.
In addition, 5 companies including Beijing Jingfeng Pharmaceutical Group, Zhejiang Haixiang Pharmaceutical, and Guizhou Tianan Pharmaceutical have submitted their listing applications for review and approval
.
Analysts believe that although more and more companies enter the market, the competition in the acarbose tablet market is becoming more and more intense, but from the perspective of sales in recent years, acarbose is still an oral drop with an annual sales of 1 billion+.
Large variety of sugar medicine
.
In the future, with the 2017 edition of the medical insurance catalogue acarbose was raised from Category B to Category A and import substitution accelerated, the industry expects that the market share of the original research Bayer will decrease year by year, while the market share of local companies will gradually increase
.
Taking the in-hospital sales data in the first three quarters of 2021 as an example, Bayer only accounts for 43%, while Hangzhou Zhongmei Huadong Pharmaceutical and Luye Pharmaceutical have actually won a combined market share of over 55%
.
In the future, with the continuous efforts of local enterprises, the market share may continue to expand
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
That is, 1 in 10 people may be diabetic
.
On the whole, domestic diabetic patients still have a large unmet demand, which also means that the market space for hypoglycemic drugs is broad
.
Therefore, in the face of the huge market for diabetes drugs, many pharmaceutical companies are competing for layout, and the market competition is becoming more and more intense
.
But at the same time, with the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years
.
A few days ago, the website of the State Food and Drug Administration showed that Chongqing Yaoyou Pharmaceutical's Acarbose Tablets and China Resources Secco Pharmaceuticals' Acarbose Tablets were approved for production on the same day as Class 4 imitations, which are regarded as over-reviews
.
It is reported that on the evening of March 21, China Resources Shuanghe announced that recently, China Resources Secco Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "China Resources Secco"), a wholly-owned subsidiary of the company, has received Acarbo Sugar Tablet "Drug Registration Certificate" (Certificate No.
: 2022S00199), which approved the production of this drug
.
According to public information, the original research of acarbose tablets was developed by Bayer.
It was first listed in Germany in 1990.
It is one of the main products in the field of diabetes drugs.
It belongs to the basic treatment of hyperglycemia and has a good effect on reducing postprandial blood sugar.
It is a heavyweight oral hypoglycemic drug
.
It can reduce the risk of cardiovascular disease.
At the same time, the product is effective for a long time and safe to use.
It is mainly used for type 2 diabetes and postprandial blood sugar treatment for people with impaired glucose tolerance
.
According to data, in 2020, the total sales of acarbose tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 4 billion yuan
.
At present, 15 domestic companies have the production approval documents for acarbose tablets, among which 13 companies including Shandong Lukang Pharmaceuticals, CSPC Ouyi Pharmaceuticals, Hunan Qianjin Xiangjiang Pharmaceuticals, and Lepu Pharmaceuticals have reviewed them
.
In addition, 5 companies including Beijing Jingfeng Pharmaceutical Group, Zhejiang Haixiang Pharmaceutical, and Guizhou Tianan Pharmaceutical have submitted their listing applications for review and approval
.
Analysts believe that although more and more companies enter the market, the competition in the acarbose tablet market is becoming more and more intense, but from the perspective of sales in recent years, acarbose is still an oral drop with an annual sales of 1 billion+.
Large variety of sugar medicine
.
In the future, with the 2017 edition of the medical insurance catalogue acarbose was raised from Category B to Category A and import substitution accelerated, the industry expects that the market share of the original research Bayer will decrease year by year, while the market share of local companies will gradually increase
.
Taking the in-hospital sales data in the first three quarters of 2021 as an example, Bayer only accounts for 43%, while Hangzhou Zhongmei Huadong Pharmaceutical and Luye Pharmaceutical have actually won a combined market share of over 55%
.
In the future, with the continuous efforts of local enterprises, the market share may continue to expand
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
